The FDA announced a new pilot program for communication of medical device recalls, but industry may be wary of a program that ...

Oxford Nanopore Technologies Ltd. has established a new collaboration with UK Biobank to create the world’s first ...

In what represents just the company’s second PCT filing, Aderet, Israel-based Averrto Medical Ltd. continues to build protection for its system for early stroke intervention that monitors blood flow ...

Meril Life Sciences Pvt Ltd. recently launched its next-generation transcatheter heart valve (THV), the Myval Octapro THV, which it says is unique and allows for better operator control for precise ...

The FDA’s August 2024 draft guidance for predetermined change control plans (PCCPs) for all device types has provoked some misgivings among industry, with both the Medical Device Manufacturers ...

The U.K.’s leading bioethics body is calling for a new law to regulate the generation of stem cell-derived human embryo models and ensure that research does not cross ethical red lines. Currently, ...

Investigators from Duke University hypothesized that hirudin-like protease inhibitors could be generated by linking exosite-binding aptamers with small-molecule active site inhibitors, thus generating ...

In October 2024, BioWorld logged 219 clinical trial updates, marking a decrease from 252 in September but a rise from 92 in August. The month featured 14 positive phase III trial outcomes and one ...

Compared to normal tissues, where the expression of ULBP2/5/6 protein is restricted, in non-small-cell lung cancer (NSCLC), head and neck cancer and squamous urothelial carcinoma, the levels of ...

Empyrean Therapeutics Inc. has acquired a first-in-class TLR2 antagonist molecule from Eos Therapies Inc. with the aim of ...

The conditional marketing approval for Ocaliva (obeticholic acid) has been revoked with immediate effect, following a standoff between the EMA and Advanz Pharma Ltd., the company that markets the ...

Shares of Outlook Therapeutics Inc. (NASDAQ:OTLK), were trading at $1.18, down $3.71, or 75%, on word of preliminary data from Norse Eight, the second phase III trial testing ONS-5010, an ophthalmic ...